1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2015

The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies. The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all manufacturing and supply deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply deal making as well as a discussion on the merits of the type of deal.

Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals. The chapter includes numerous case studies to enable understanding of both pure manufacturing and supply deals and multicomponent deals where manufacturing and supply forms a part.

Chapters 5 and 6 provide a review of the leading manufacturing and supply deals since 2010. Deals are listed by headline value, signed by big pharma and big biotech, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapters 9 and 10 provide a comprehensive and detailed review of manufacturing and supply deals signed and announced since 2010 for all pharma, biotech, device and diagnostics companies where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.

In addition the report includes a comprehensive listing of all manufacturing and supply deals announced since 2010.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply alliances. Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2015 provides the reader with the following key benefits:

In-depth understanding of manufacturing and supply partnering deal trends since 2010
Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
Identify leading manufacturing and supply deals by value since 2010
Identify the most active manufacturing and supply dealmakers since 2010
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Full listing of manufacturing and supply deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
Comprehensive access to over 2,500 manufacturing and supply deals entered into by the world’s biopharma companies, together with contract documents if available
Detailed access to actual manufacturing and supply contracts entered into by the leading fifty big pharma and big biotech companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in manufacturing and supply dealmaking
2.1. Introduction
2.2. Difference between manufacturing and supply deals
2.3. Trends in manufacturing deals since 2010
2.4. Trends in supply deals since 2010
2.4.1. When supply can be useful
2.5. Attributes of pure manufacturing and supply deals
2.6. Attributes of manufacturing and supply in multi-component deals
2.7. Reasons for including manufacturing and supply options in a multi-component deal
2.8. The future of manufacture and supply as part of multicomponent deals

Chapter 3 - Overview of manufacturing and supply deal structure
3.1. Introduction
3.2. Pure versus multi-component manufacturing deals
3.3. Pure manufacturing agreement structure
3.3.1. Example manufacturing agreements
3.3.1.a. Case study 1: Amyris Brazil - Biomin Nutricao Animal Do Brasil
3.3.1.b. Case study 2: Patheon - Orexigen Therapeutics
3.4. Manufacturing rights as part of a wider alliance agreement
3.4.1. Example multicomponent manufacturing clauses
3.4.1.a. Case study 3: Agenus Bio - NewVac
3.4.1.b. Case study 4: Elite Pharmaceuticals - Hi-Tech Pharmacal

Chapter 4 - Overview of supply deal structure
4.1. Introduction
4.2. Supply agreement structure
4.2.1. Example supply agreements
4.2.1.a. Case study 5: Omthera Pharmaceuticals - Catalent Pharma solutions
4.2.1.b. Case study 6: Endo Pharmaceuticals - Noramco
4.3. Supply rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 7: Auxilium Pharmaceuticals - Asahi Kasei
4.3.1.b. Case study 8: Durata Therapeutics - Hospira

Chapter 5 - Leading manufacturing deals
5.1. Introduction
5.2. Top manufacturing deals by value
5.3. Most active manufacturing dealmakers
5.4. Big pharma manufacturing deal activity
5.5. Big biotech manufacturing deal activity

Chapter 6 - Leading supply deals
6.1. Introduction
6.2. Top supply deals by value
6.3. Most active supply dealmakers
6.4. Big pharma supply deal activity
6.5. Big biotech supply deal activity

Chapter 7 - Big pharma manufacturing and supply deals
7.1. Introduction
7.2. How to use manufacturing and supply deals
7.3. Big pharma company manufacturing and supply deal profiles

Chapter 8 - Big biotech manufacturing and supply deals
8.1. Introduction
8.2. How to use big biotech partnering deals
8.3. Big biotech manufacturing and supply partnering company profiles

Chapter 9 - Manufacturing deals contracts directory
9.1. Introduction
9.2. Manufacturing deals with a contract document by company A-Z
9.3. Manufacturing deals with a contract document by stage of development
9.4. Manufacturing deals with a contract document by therapeutic target
9.5. Manufacturing deals with a contract document by technology type

Chapter 10 - Supply deals contracts directory
10.1. Introduction
10.2. Supply deals with a contract document by company A-Z
10.3. Supply deals with a contract document by stage of development
10.4. Supply deals with a contract document by therapeutic target
10.5. Supply deals with a contract document by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

View the accompanying appendices for:

Appendix 1 - Manufacturing deals by company A-Z
Appendix 2 - Manufacturing deals by therapy area
Appendix 3 - Manufacturing deals by stage of development at signing
Appendix 4 - Manufacturing deals by technology type
Appendix 5 - Supply deals by company A-Z
Appendix 6 - Supply deals by therapy area - supply
Appendix 7 - Supply deals by stage of development at signing - supply
Appendix 8 - Supply deals by technology type - supply
Appendix 9 -Dealmaking references
Appendix 10 - Resources
Appendix 11 - Deal type definitions
Appendix 12 - Example manufacturing and supply contract document

TABLE OF FIGURES

Figure 1: Definition of manufacturing and supply
Figure 2: Types of manufacturing agreement
Figure 3: Trends in manufacturing deal announcements, 2010-2015
Figure 4: Manufacturing deals signed by phase of development, 2010-2015
Figure 5: Trends in supply deal announcements, 2010-2015
Figure 6: Supply deals signed at what phase of development, 2010-2015
Figure 7: Components of the manufacturing deal structure
Figure 8: Components of the supply deal structure
Figure 9: Top manufacturing deals by value since 2010
Figure 10: Most active manufacturing dealmakers 2010-2015
Figure 11: Big pharma - top 50 - manufacturing deals 2010 to 2015
Figure 12: Big pharma manufacturing deal frequency - 2010 to 2015
Figure 13: Big biotech - top 50 - manufacturing deals 2010 to 2015
Figure 14: Top supply deals by value since 2010
Figure 15: Most active supply dealmakers 2010-2015
Figure 16: Big pharma - top 50 - supply deals 2010 to 2015
Figure 17: Big pharma supply deal frequency - 2010 to 2015
Figure 18: Big biotech - top 50 - supply deals 2010 to 2015
Figure 19: Big biotech supply deal frequency - 2010 to 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.